HighTower Advisors LLC Invests $607,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

HighTower Advisors LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,485 shares of the medical equipment provider’s stock, valued at approximately $607,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 53.7% in the second quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after buying an additional 796,000 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Lantheus by 1.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after acquiring an additional 19,071 shares during the last quarter. Swedbank AB raised its position in shares of Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares during the period. LSV Asset Management lifted its holdings in shares of Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock valued at $51,462,000 after purchasing an additional 139,647 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its position in shares of Lantheus by 7.6% in the 2nd quarter. Clearbridge Investments LLC now owns 560,609 shares of the medical equipment provider’s stock valued at $45,011,000 after purchasing an additional 39,369 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Stock Performance

Lantheus stock opened at $91.94 on Friday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The firm has a market cap of $6.39 billion, a PE ratio of 15.30 and a beta of 0.45. The firm’s 50 day moving average price is $96.95 and its two-hundred day moving average price is $98.23.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial restated a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Redburn Atlantic began coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday. They set a “buy” rating and a $143.00 target price on the stock. Finally, JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.